UBS Group’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

UBS Group’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-142	Closed	-$75	–	11220
2025 Q1	$75	Sell	142 -4,497	-97%	-$7.41K	﹤0.01%	9978
2024 Q4	$24.4K	Buy	4,639 +4,627	+38,558%	+$30.4K	﹤0.01%	7749
2024 Q3	$171	Buy	+12	New	+$165	﹤0.01%	9095
2024 Q2	–	Sell	-125	Closed	-$3.14K	–	9442
2024 Q1	$12.6K	Sell	125 -22	-15%	-$1.39K	﹤0.01%	7129
2023 Q4	$3.48K	Sell	147 -140	-49%	-$2.35K	﹤0.01%	7964
2023 Q3	$5.79K	Buy	+287	New	+$5.57K	﹤0.01%	7344
2022 Q4	–	Sell	-78	Closed	-$2K	–	11267
2022 Q3	$2K	Buy	+78	New	+$2.24K	﹤0.01%	9802

Other funds holding VINC

BTC

Bank & Trust Company Litchfield, Illinois $158M AUM 35.48% 1-Year Est. Return

UBS Group's VINC Position: Q2 2025 in Review

UBS Group sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2025, closing a stake of 142 shares — an estimated $75 sold.

UBS Group first reported a position in VINC in Q3 2022 and held it in 7 quarters. The position peaked at $24.4K in Q4 2024. 1 fund tracked by Wall St. Rank holds VINC as of Q2 2025.

UBS Group reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
UBS Group sold 142 Vincerx Pharma, Inc. Common Stock shares in Q2 2025, an estimated $75.
UBS Group first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2022 and held it in 7 quarters.
UBS Group's Vincerx Pharma, Inc. Common Stock position peaked at $24.4K in Q4 2024.
1 fund tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.